Anti-TNF-α Antibodies Suppress the Development of Experimental Autoimmune Myasthenia Gravis

Drachman, 1994, Myasthenia gravis, N. Engl. J. Med, 330, 1797, 10.1056/NEJM199406233302507 Li, 1998, Cytokine and chemokine mRNA expressing cells in muscle tissues of experimental autoimmune myasthenia gravis, J. Neurol. Sci, 161, 40, 10.1016/S0022-510X(98)00181-6 Wang, 2000, Tumor necrosis factor receptor-1 is critically involved in the development of experimental autoimmune myasthenia gravis, Int. Immunol, 12, 1381, 10.1093/intimm/12.10.1381 Zhang, 1997, Linomide suppresses both Th1 and Th2 cytokines in experimental autoimmune myasthenia gravis, J. Neuroimmunol, 73, 175, 10.1016/S0165-5728(96)00197-X van Deventer, 1999, Anti-TNF antibody treatment of Crohn's disease, Ann. Rheum. Dis, 58, 114, 10.1136/ard.58.2008.i114 Feldmann, 1999, The rationale for the current boom in anti-TNFalpha treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFalpha and minimise hazards?, Ann. Rheum. Dis, 58, 27, 10.1136/ard.58.2008.i27 Harriman, 1999, Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment, Ann. Rheum. Dis, 58, 61, 10.1136/ard.58.2008.i61 Wildbaum, 1999, Augmentation of natural immunity to a pro-inflammatory cytokine (TNF-alpha) by targeted DNA vaccine confers long-lasting resistance to experimental autoimmune encephalomyelitis, Gene Ther, 6, 1128, 10.1038/sj.gt.3300915 Korner, 1997, Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system, Eur. J. Immunol, 27, 1973, 10.1002/eji.1830270822 Lindstrom, 1981, Production and assay of antibodies to acetylcholine receptors, Methods Enzymol, 74, 432, 10.1016/0076-6879(81)74031-X Wang, 2001, Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis, J. Immunol, 166, 6430, 10.4049/jimmunol.166.10.6430 Im, 2001, Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18, FASEB J, 15, 2140, 10.1096/fj.01-0072com Macdonald, 1988, The measurement of relative antibody affinity by ELISA using thiocyanate elution, J. Immunol. Methods, 106, 191, 10.1016/0022-1759(88)90196-2 Saoudi, 1999, Experimental autoimmune myasthenia gravis may occur in the context of a polarized Th1- or Th2-type immune response in rats, J. Immunol, 162, 7189, 10.4049/jimmunol.162.12.7189 Wu, 1997, Tolerance to a dominant T cell epitope in the acetylcholine receptor molecule induces epitope spread and suppresses murine myasthenia gravis, J. Immunol, 159, 3016, 10.4049/jimmunol.159.6.3016 Shi, 1998, Nasal tolerance in experimental autoimmune myasthenia gravis (EAMG): induction of protective tolerance in primed animals, Clin. Exp. Immunol, 111, 506, 10.1046/j.1365-2249.1998.00521.x Yang, 1998, How subtle differences in MHC class II affect the severity of experimental myasthenia gravis, Clin. Immunol. Immunopathol, 86, 45, 10.1006/clin.1997.4451 Sidman, 1984, Gamma-interferon is one of several direct B cell-maturing lymphokines, Nature, 309, 801, 10.1038/309801a0 Snapper, 0000, Towards a comprehensive view of immunoglobulin class switching, Immunol. Today, 14, 15, 10.1016/0167-5699(93)90318-F Rizzo, 1992, Generation of B cell memory and affinity maturation. Induction with Th1 and Th2 T cell clones, J. Immunol, 148, 3733, 10.4049/jimmunol.148.12.3733 Jelinek, 1987, Enhancement of human B cell proliferation and differentiation by tumor necrosis factor-alpha and interleukin 1, J. Immunol, 139, 2970, 10.4049/jimmunol.139.9.2970 Graus, 1993, Characterization of anti-acetylcholine receptor (AChR) antibodies from mice differing in susceptibility for experimental autoimmune myasthenia gravis (EAMG), Clin. Exp. Immunol, 92, 506, 10.1111/j.1365-2249.1993.tb03429.x Krolick, 1994, Examination of characteristics that may distinguish disease-causing from benign AChR-reactive antibodies in experimental autoimmune myasthenia gravis, Adv. Neuroimmunol, 4, 475, 10.1016/0960-5428(94)00033-K Howard, 1992, Biological properties of interleukin 10, Immunol. Today, 13, 198, 10.1016/0167-5699(92)90153-X Hagenbaugh, 1997, Altered immune responses in interleukin 10 transgenic mice, J. Exp. Med, 185, 1210, 10.1084/jem.185.12.2101 Matusevicius, 1996, Tumor necrosis factor-alpha, lymphotoxin, interleukin (IL)-6, IL-10, IL-12 and perforin mRNA expression in mononuclear cells in response to acetylcholine receptor is augmented in myasthenia gravis, J. Neuroimmunol, 71, 191, 10.1016/S0165-5728(96)00152-X Poussin, 2000, Suppression of experimental autoimmune myasthenia gravis in IL-10 gene-disrupted mice is associated with reduced B cells and serum cytotoxicity on mouse cell line expressing AChR, J. Neuroimmunol, 111, 152, 10.1016/S0165-5728(00)00385-4 Zhang, 2001, Interleukin 10 aggravates experimental autoimmune myasthenia gravis through inducing Th2 and B cell responses to AChR, J. Neuroimmunol, 113, 10, 10.1016/S0165-5728(00)00411-2 Huang, 1999, Increased levels of circulating acetylcholine receptor (AChR)-reactive IL-10-secreting cells are characteristic for myasthenia gravis (MG), Clin. Exp. Immunol, 118, 304, 10.1046/j.1365-2249.1999.01062.x Zhang, 1997, Cytokines and the pathogenesis of myasthenia gravis, Muscle Nerve, 20, 543, 10.1002/(SICI)1097-4598(199705)20:5<543::AID-MUS2>3.0.CO;2-9 Weissert, 1997, Altered tumor growth factor beta mRNA expression is associated with thymectomy-related clinical remission in myasthenia gravis, J. Neurol. Sci, 151, 49, 10.1016/S0022-510X(97)00104-4